Gulf International Bank UK Ltd Sells 951 Shares of Becton, Dickinson and Company (NYSE:BDX)

Gulf International Bank UK Ltd trimmed its holdings in shares of Becton, Dickinson and Company (NYSE:BDX) by 4.1% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 22,145 shares of the medical instruments supplier’s stock after selling 951 shares during the quarter. Gulf International Bank UK Ltd’s holdings in Becton, Dickinson and Company were worth $5,339,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Livelsberger Financial Advisory acquired a new stake in shares of Becton, Dickinson and Company during the 3rd quarter worth approximately $26,000. Sound Income Strategies LLC boosted its holdings in shares of Becton, Dickinson and Company by 35.8% in the 3rd quarter. Sound Income Strategies LLC now owns 167 shares of the medical instruments supplier’s stock valued at $40,000 after purchasing an additional 44 shares in the last quarter. Opal Wealth Advisors LLC bought a new position in shares of Becton, Dickinson and Company in the 2nd quarter valued at $45,000. Abound Wealth Management raised its holdings in shares of Becton, Dickinson and Company by 96.0% during the 2nd quarter. Abound Wealth Management now owns 196 shares of the medical instruments supplier’s stock worth $46,000 after buying an additional 96 shares in the last quarter. Finally, Chilton Capital Management LLC lifted its position in shares of Becton, Dickinson and Company by 1,233.3% during the 2nd quarter. Chilton Capital Management LLC now owns 200 shares of the medical instruments supplier’s stock worth $47,000 after buying an additional 185 shares during the last quarter. Institutional investors and hedge funds own 86.97% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages have commented on BDX. Citigroup raised Becton, Dickinson and Company from a “neutral” rating to a “buy” rating and boosted their target price for the stock from $255.00 to $275.00 in a research note on Tuesday, October 1st. Raymond James dropped their price objective on shares of Becton, Dickinson and Company from $275.00 to $270.00 and set an “outperform” rating for the company in a research note on Friday, August 2nd. Stifel Nicolaus boosted their target price on shares of Becton, Dickinson and Company from $270.00 to $280.00 and gave the stock a “buy” rating in a research note on Friday, July 26th. Evercore ISI increased their price target on Becton, Dickinson and Company from $286.00 to $290.00 and gave the company an “outperform” rating in a research note on Tuesday, October 1st. Finally, StockNews.com raised Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a report on Thursday, August 8th. Nine research analysts have rated the stock with a buy rating, According to MarketBeat, the company currently has a consensus rating of “Buy” and an average price target of $282.63.

Becton, Dickinson and Company Trading Up 1.3 %

BDX opened at $237.30 on Wednesday. The company has a fifty day moving average of $237.51 and a 200-day moving average of $235.12. Becton, Dickinson and Company has a twelve month low of $218.75 and a twelve month high of $259.92. The company has a quick ratio of 1.36, a current ratio of 1.85 and a debt-to-equity ratio of 0.70. The stock has a market cap of $68.59 billion, a PE ratio of 48.83, a price-to-earnings-growth ratio of 1.76 and a beta of 0.43.

About Becton, Dickinson and Company

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.